Clovis Oncology announces first patient enrolled in cancer trial

Clovis Oncology announces first patient enrolled in cancer trial

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis Rubraca (rucaparib), a... Read More

Wednesday August 8, 2018 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy

Clovis Oncology receives European validation for Rubraca cancer drug

Clovis Oncology receives European validation for Rubraca cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ... Read More

Thursday July 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with... Read More

Tuesday May 29, 2018 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rucaparib

Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment

Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) announced the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with... Read More

Monday April 9, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology’s Rubraca cancer treatment gets green light from EU

Clovis Oncology’s Rubraca cancer treatment gets green light from EU

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Unions (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive... Read More

Monday March 26, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis: EU Medicines Agency approval sought for rucaparib cancer drug

Clovis: EU Medicines Agency approval sought for rucaparib cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Unions (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that... Read More

Tuesday December 19, 2017 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rucaparib

Clovis announces FDA priority review for rucaparib cancer drug

Clovis announces FDA priority review for rucaparib cancer drug

BOULDER -- Clovis Oncology (NASDAQ: CLVS) announced theU.S. Food and Drug Administration(FDA) has accepted the companys supplemental New Drug Application (sNDA) for rucaparib and... Read More

Wednesday December 6, 2017 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy

Clovis announces FDA application for accelerated approval of cancer drug

Clovis announces FDA application for accelerated approval of cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the U.S. Food and Drug Administration (FDA) has accepted Clovis New Drug Application (NDA) for accelerated approval of rucaparib and... Read More

Thursday August 25, 2016 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy, Foundation Medicine